Login

Creating, facilitating, and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe

Custom icon
Early Dialogues

Custom icon
Submission & Methodology

Custom icon
Assessments

Custom icon
National Implementation

OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.

By admin  /  August 14, 2019
OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.

Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available

By admin  /  August 9, 2019
Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available

PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

By admin  /  August 8, 2019
PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)

By admin  /  August 7, 2019
The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)

PTJA07 – “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies” project plan is now available.

By admin  /  July 29, 2019
PTJA07 – “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies” project plan is now available.

Services

Assessments

Tools

Have Questions? Check our FAQ